Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2011, Article ID 896040, 9 pages
http://dx.doi.org/10.1155/2011/896040
Clinical Study

Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana

1Department of Child Health, University of Ghana Medical School, Accra, Ghana
2University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854-8021, USA
3Yale Center for Analytical Sciences, Yale University School of Medicine, New Haven, CT 06510-3206, USA
4Departments of Pediatrics and Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510-3206, USA

Received 26 January 2011; Revised 24 February 2011; Accepted 3 March 2011

Academic Editor: Eric Daar

Copyright © 2011 Lorna Renner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. CD4+ T-lymphocyte monitoring is not routinely available in most resource-limited settings. We investigated predictors of time to CD4+ T-lymphocyte recovery in HIV-infected children on highly active antiretroviral (HAART) at Korle-Bu Teaching Hospital, Ghana. Methods. Time to CD4+ T-lymphocyte recovery was defined as achieving percent CD4+ T-lymphocytes of 25%. We used Cox proportional hazard models for identifying significant predictor variables. Results. Of the 233 children with complete CD4+ T-lymphocyte data, the mean age at HAART initiation was 5.5 (SD=3.1) years. The median recovery time was 60 weeks (95% CL: 55–65). Evidence at baseline of severe suppression in CD4+ T-lymphocyte count adjusted for age, age at HAART initiation, gender, and having parents alive were statistically significant in predicting time to CD4+ T-lymphocyte recovery. Conclusions. A targeted approach based on predictors of CD4+ T-lymphocyte recovery can be a viable and cost-effective way of monitoring HAART in HIV-infected children in resource-limited settings.